| Posted on: | Category: MAIC
MAIC
Reimbursement authorities need the best available evidence when comparing treatments. This evidence is arguably best obtained from randomised controlled trials. However, for many valid scientific and commercial reasons, ...
| Posted on: | Category: Epidemiology
SARS-CoV-2
Since the emergence of the corona pandemic, there has been a worldwide question regarding when the pandemic would come to an end. In the meantime, such hopes are increasingly being supplanted by concerns that this infectious ...
| Posted on: | Category: HTA
In the benefit assessment of drugs, it may happen that a benefit must be re-examined in a subpopulation, for example if the approval is restricted to a subpopulation which particularly benefits from the treatment. In these ...
